Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENZ215 versus Prolia in postmenopausal women with osteoporosis
2021-004811-26Phase 3Withdrawn
- Sponsor
- Alkem Laboratories
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in postmenopausal osteoporosis comparing ENZ215 arm with Prolia arm (2 arms). Primary endpoint: Percent change in lumbar spine bone mineral density. Planned start Dec 2021; status: withdrawn.
02
Drugs
denosumabdenosumab-nxxp
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on 2021-004811-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004811-26.